Month: December 2020

DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that Abid Ansari, Chief Financial Officer, notified the Company that he will be leaving the organization after nearly five years to pursue a new career opportunity. Abid will continue with Precision through the end of 2020 to ensure a smooth transition. Alex Kelly, the Company’s Chief Corporate Affairs Officer, will serve as the Company’s Interim Chief Financial Officer with Shane Barton, the Company’s Vice President and Corporate Controller, serving as interim principal accounting officer, reporting directly to Alex.“On behalf of the entire executive leadership team, I want to thank Abid for his...

ABU DHABI, United Arab Emirates, Dec. 13, 2020 (GLOBE NEWSWIRE) — Computer vision developer, SAFR from RealNetworks, Inc. (NASDAQ: RNWK) and IT solutions provider, EPM have secured a high profile contract with a federal agency in the Government of the United Arab Emirates, to provide face-based authentication for secure access at entry points of their HQ. SAFR’s face recognition and mask detection capabilities have been embedded in EPM’s security platform to allow for registered users to be recognized at secure access points using just their face — even while wearing virus-preventing face masks. The joint solution was implemented using the existing video surveillance infrastructure at the agency location after a successful three-month trial where SAFR from RealNetworks’ face recognition was able to provide secure authentication...

VANCOUVER, British Columbia, Dec. 13, 2020 (GLOBE NEWSWIRE) — Millrock Resources Inc. (TSX-V: MRO, OTCQB: MLRKF) (“Millrock” or the “Company”), along with partner Resolution Mineral Inc. (ASX: RML “Resolution”), has completed field exploration activities for the year at the 64North project. The project targets large-scale gold deposits in the Goodpaster District. The claims comprising the property are adjacent to the Pogo Mine, a multi-million ounce gold mine operated by Northern Star Resources.Millrock President & CEO Gregory Beischer commented, “We are pleased to have been able to execute this exploration program despite the additional risk and challenge posed by COVID. A strong initial drill test of the West Pogo prospects was completed, and new drill targets were defined at other prospects on this district-scale...

SILICON SLOPES, Utah, Dec. 13, 2020 (GLOBE NEWSWIRE) — Pluralsight, Inc. (NASDAQ: PS), the technology workforce development company, today announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), a leading global investment firm focused on enterprise software, data and technology-enabled businesses.Under the terms of the agreement, Vista, in partnership with its institutional co-investors including Partners Group, will acquire all outstanding shares of Pluralsight common stock for $20.26 per share in an all-cash transaction valued at approximately $3.5 billion. The purchase price represents a premium of approximately 25% to the company’s volume weighted average closing stock price for the 30 trading days prior to today’s announcement.Pluralsight, which is headquartered in Utah...

NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has entered into a share purchase agreement with institutional investors to purchase approximately $16.2 million of its common stock in a registered direct offering at a purchase price of $7.00 per share.Under the terms of the share purchase agreement, SELLAS has agreed to sell 2,320,000 shares of its common stock. The gross proceeds to the Company from the registered direct offering are expected to be approximately $16.2 million before deducting the placement agent’s fees and other offering expenses. The registered direct offering is expected...

SHANGHAI, China, Dec. 14, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Independent Data Monitoring Committee (IDMC) has determined that Toripalimab (product code: JS001) in combination with standard chemotherapy as the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) has reached its pre-specified primary endpoint of Progression Free Survival (PFS) at the interim analysis of a randomized, double-blind, multi-center, phase III clinical study “CHOICE-01” (Clinicaltrial.gov identifier: NCT03856411). The Company will initiate the process to submit a supplemental New Drug Application (NDA) to the National Medical Products...

Ghent, 13 December 2020, 5 p.m.Press release / Regulated informationABO-GROUP acquires French engineering firm GEO+ Environnement.ABO-GROUP will acquire all the shares of the French GEO+ Environnement company at the beginning of January 2021. GEO+ Environnement has its head offices in Gardouch, near Toulouse, in the French department of Haute-Garonne, and has four offices in Central, North, East and South-West France.Thanks to around 25 hydrogeologists, ecologists and geologists, the added expertise and knowledge in the mining, quarrying and dyke sectors can thereby also be offered to the other ABO-GROUP home countries.GEO+ Environnement is an independent consultancy specialised in environmental advice in the mineral industry (mines and quarries), with expertise in environment, geology and hydraulic engineering. It is the French reference...

Gent, 13 december 2020, 17 uPersbericht / Gereglementeerde informatieABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over.ABO-GROUP verwerft begin januari 2021 alle aandelen van het Franse GEO+ Environnement. GEO+ Environnement heeft haar hoofdzetel in Gardouch, nabij Toulouse, in het Franse departement Haute-Garonne, met vier kantoren verspreid in het center, het Noorden, Oosten en Zuidwesten van Frankrijk.De toegevoegde expertise en kennis in de sector van mijnbouw, steengroeven en dijken kan dankzij een 25-tal hydrogeologen, ecologen en geologen, hierbij ook in de andere thuislanden van ABO-GROUP aangeboden worden.GEO+ Environnement is een onafhankelijk adviesbureau gespecialiseerd in milieuadvies in de minerale industrie (mijnen en steengroeven), met een expertise in milieu, geologie en waterbouw. Het is hét Frans referentiebureau...

Gand, le 13 décembre 2020, 17 heuresCommuniqué de presse / Information réglementéeABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement.ABO-GROUP acquerra la totalité des actions de la société française GEO+ Environnement au début du mois de janvier 2021. GEO+ Environnement a son siège social à Gardouch, près de Toulouse, dans le département français de la Haute-Garonne, avec quatre bureaux dans le centre, le nord, l’est et le sud-ouest de la France.À la clef : une expertise et des connaissances supplémentaires dans le secteur des mines, des carrières et des digues qui pourront désormais être également proposées dans les autres pays d’activité d’ABO-GROUP, grâce à quelque 25 hydrogéologues, écologistes et géologues.GEO+ Environnement est un bureau d’études indépendant spécialisé dans le conseil environnemental...

– TC-210 induced tumor regression in all of the first eight patients– Ovarian cancer patient achieved confirmed RECIST partial response (PR)– Overall response rate (ORR) 50% in patients infused with TC-210 and lymphodepletion      – Continued manageable toxicity profile      – Phase 1 trial amended to accelerate treatment– TCR2 to host conference call Monday, December 14 starting at 8:00am E.T. live webcast availableCAMBRIDGE, Mass., Dec. 13, 2020 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the ongoing Phase 1 portion of the TC-210 ( gavocabtagene autoleucel or “gavo-cel”) Phase 1/2 clinical trial for mesothelin-expressing...